All In Biotech

NDA 220934 · Eli Lilly and CO

Foundayo

Orforglipron Calcium · Oral

Novel

CDER novel approval, Apr 1, 2026: To reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity

Last checked: Nov 20, 2026Latest source record: Aug 4, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

Apr 1, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

53

27 Phase 3, 10 recruiting

FAERS reports

3,056

138 serious, 4 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF THYROID C-CELL TUMORS In products with glucagon-like peptide-1 (GLP-1) receptor agonist activity that are pharmacologically active in rats and mice, rodent thyroid C-cell tumors (adenomas and carcinomas) have been observed at clinically relevant exposures and are considered GLP-1 receptor-dependent effects in rodents. Orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents [see Nonclinical Toxicology ( 13.1 )] . While orforglipron is pharmacologically active at the human GLP-1 receptor, the human relevance of GLP-1 receptor-dependent thyroid C-cell tumors observed in rodents has not been determined [see Warnings and Precautions ( 5.1 ), Nonclinical Toxicology ( 13.1 )] . FOUNDAYO is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia...

What it is approved for

From the label in effect Jul 29, 2026.

FOUNDAYO TM is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. FOUNDAYO™ is a GLP-1 receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) Limitations of Use Concomitant use with another GLP-1 receptor agonist is not recommended. ( 1 ) Limitations of Use Concomitant use with another GLP-1 receptor agonist is not recommended.

Mechanism: FOUNDAYO is a GLP-1 receptor agonist that binds to and activates the human GLP-1 receptor. GLP-1 is a physiological regulator of appetite and caloric intake. GLP-1 receptors are present in brain regions that regulate appetite. In animal studies, orforglipron distributed to and activated neurons in brain regions that regulate appetite and food intake.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 1, 2026 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
6 products under this application
  • FOUNDAYO · ORFORGLIPRON CALCIUM EQ 2.5MG BASE · TABLET, ORAL · Prescription
  • FOUNDAYO · ORFORGLIPRON CALCIUM EQ 14.5MG BASE · TABLET, ORAL · Prescription
  • FOUNDAYO · ORFORGLIPRON CALCIUM EQ 5.5MG BASE · TABLET, ORAL · Prescription
  • FOUNDAYO · ORFORGLIPRON CALCIUM EQ 0.8MG BASE · TABLET, ORAL · Prescription
  • FOUNDAYO · ORFORGLIPRON CALCIUM EQ 17.2MG BASE · TABLET, ORAL · Prescription
  • FOUNDAYO · ORFORGLIPRON CALCIUM EQ 9MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Orforglipron" as an intervention, any sponsor and status, largest first.

All 53 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea717
  • drug ineffective551
  • constipation331
  • vomiting282
  • weight increased246
  • fatigue227
  • weight loss poor218
  • diarrhoea212
  • headache187
  • illness147
  • abdominal pain upper137
  • dizziness130

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20251
20263,055

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 50 on PubMed

Sponsor: Eli Lilly

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.